Wednesday, September 11, 2024 Kinetic profiling of RAS mutations with circulating tumor DNA - CO26Purpose: In metastatic colorectal cancer (mCRC), RAS mutations drive resistance to anti-epidermal growth factor receptor antibodies. It is unclear whether RAS mutations ever become clonally undetectable.Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Colorectal Cancer Is Transient.Wu FTH, Topham JT, O'Callaghan CJ, Feilotter H, Kennecke HF, Drusbosky L, Renouf DJ, Jonker DJ, Tu D, Chen EX, Loree JM.JCO Precis Oncol. 2024 Aug;8:e2400031. doi: 10.1200/PO.24.00031.PMID: 39178370 Free PMC article. Clinical Trial.
